Attributes | Values |
---|
rdf:type
| |
Description
| - The effects of lipid-lowering treatment were evaluated in patients with schizophrenia treated with antipsychotics. Forty-six patients with schizophrenia and with severe dyslipidaemia were examined at baseline and three months after initiation of statin therapy. A significant decrease in triglycerides, total cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and in associated ratios was observed. No significant changes occurred in components of metabolic syndrome other that triglycerides
- The effects of lipid-lowering treatment were evaluated in patients with schizophrenia treated with antipsychotics. Forty-six patients with schizophrenia and with severe dyslipidaemia were examined at baseline and three months after initiation of statin therapy. A significant decrease in triglycerides, total cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and in associated ratios was observed. No significant changes occurred in components of metabolic syndrome other that triglycerides (en)
- Prezentovaná studie se zabývá efektem hypolipidemik u pacientů se schizofrenií na antipsychotické terapii. Čtyřicet šest pacientů s diagnózou schizofrenie a závažnou dyslipidémií bylo vyšetřeno před, a 3 měsíce po nasazení statinů. U pacientů došlo k signifikantnímu poklesu hladiny triglyceridů, celkového cholesterolu, low density lipoprotein cholesterolu, non-high-density lipoprotein cholesterolu, a také ke snížení souvisejících poměrů. Komponenty metabolického syndromu, kromě snížení hladiny triglyceridů, léčba neovlivnila (cs)
|
Title
| - Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia
- Farmakologická léčba závažné dyslipidémie u pacientů trpících schizofrenií (cs)
- Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia (en)
|
skos:prefLabel
| - Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia
- Farmakologická léčba závažné dyslipidémie u pacientů trpících schizofrenií (cs)
- Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia (en)
|
skos:notation
| - RIV/00216208:11150/07:00003539!RIV08-MSM-11150___
|
http://linked.open.../vavai/riv/strany
| |
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11150/07:00003539
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - cardiovascular risk; dyslipidaemia; metabolic syndrome; schizophrenia; statins (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - US - Spojené státy americké
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - International Clinical Psychopharmacology
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
http://linked.open...n/vavai/riv/zamer
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |